INDIANA HEALTH COVERAGE PROGRAMS (IHCP) NARCOLEPSY AGENTS PRIOR AUTHORIZATION REQUEST FORM

Land and the second	MDw Fax to: (858) c/o MedImpact Healtl Attn: Prior Authoriz 10181 Scripps Gateway Cou Phone: (808)	790-7100 hcare Systems, Inc. zation Department ırt, San Diego, CA 92131	A McLaren Compa
Today's Date	be completed by the prescribing provide	der.	
Patient's Medicaid #	**All sections must be complete	ed or the request will be return Date of Birth	.ed**
Patient's Name		Prescriber's Name	
Prescriber's IN License #		Specialty	
Prescriber's NPI #		Prescriber's Signature	
Return Fax #		Return Phone #	
Check box if requesting	retro-active PA	Date(s) of service requested for retro-active eligibility (if applicab	le):
eligibility timelines) with	ts for retroactive claims (dates of servi dates of service prior to 30 calendar da ays or less and going forward).		

Requested Medication	Quantity	Dosing

PA Requirements for Nuvigil (armodafinil):

The member is 18 years of age or older and has one of the following diagnoses:

□ Bipolar depression in conjunction with appropriate medical intervention(s)

- List any other medical intervention(s) being utilized for bipolar depression (e.g., mood stabilizers):
- □ Narcolepsy with excessive daytime sleepiness
- □ Obstructive sleep apnea/hypopnea syndrome with residual excessive daytime sleepiness in conjunction with appropriate medical intervention(s)
 - List any other medical intervention(s) being utilized for obstructive sleep apnea (e.g., PAP, OPT, etc.)?

□ Shift work sleep disorder

PA Requireme	ents for Provigil (modafinil):
Select ONE of	the following:
1)	The member is 6 years of age or older and has one of the following diagnoses:
	 Attention deficit hyperactivity disorder (ADHD)
2)	 Narcolepsy with excessive daytime sleepiness The member is 18 years of age or older and has one of the following diagnoses:
	Depression-related fatigue in conjunction with appropriate medical intervention(s)
	 List any other medical intervention(s) being utilized for depression (e.g., antidepressants):
	□ Idiopathic hypersomnia
	 Obstructive sleep apnea/hypopnea syndrome with residual excessive daytime sleepiness in conjunction with appropriate medical intervention(s) List any other medical intervention(s) being utilized for obstructive sleep apnea (e.g., PAP, OPT, etc.)?
	□ Shift work sleep disorder
	□ Sleep deprivation
	Steinert myotonic dystrophy syndrome
	 Unipolar or bipolar depression in conjunction with appropriate medical intervention(s) List any other medical intervention(s) being utilized for unipolar/bipolar depression (e.g., antidepressants/mood stabilizers):

PA Requirements for Sunosi (solriamfetrol):

The member is 18 years of age or older and has one of the following diagnoses:

□ Narcolepsy with excessive daytime sleepiness

□ Obstructive sleep apnea/hypopnea syndrome with residual excessive daytime sleepiness in conjunction with appropriate medical intervention(s)

- List any other medical intervention(s) being utilized for obstructive sleep apnea (e.g., PAP, OPT, etc.)?
- Has the member had a previous trial and failure with any of the following in the past year:
 - Modafinil
 Dates of use: ______
 - Armodafinil
 Dates of use: _____

If no, please provide any other medical justification for use: _____

PA Requireme	ents for Wakix (pitolisa	int):	
The member is	18 years of age or olde	r and has one c	f the following diagnoses:
Narcole	psy with cataplexy or ex	cessive daytime	e sleepiness
	tive sleep apnea/hypopi priate medical interventio		vith residual excessive daytime sleepiness in conjunction
•			being utilized for obstructive sleep apnea (e.g., PAP,
•	Has the member had a	a previous trial a	and failure with any of the following in the past year:
	Modafinil		
	Armodafinil	Dates of use: _	
	If no, please documen	t any other med	lical justification for use:
	ents for Xyrem (sodiun	n oxybate):	
Initial Authoria	Zation ONE of the following:		
	*	s of age or olde	r and has narcolepsy with cataplexy or excessive
	daytime sleepiness dia	agnosis 🗆 Yes	□ No
	Please provide rec	quested dose pe	er day:
	Please provide me	ember's weight (include date of collection):
2)		-	er and has fibromyalgia diagnosis □ Yes □ No rial and failure with ONE of the following?
		ne	Dates of use:
			Medication name and dates of use:
			Medication name and dates of use:
	□ Anticonvul (gabapentin, p		Medication name and dates of use:
	NSAIDs ar	nd APAP	Dates of use:
			f the above agents, please provide medical justification ent in that class was not trialed.

• Please provide requested dose per day: _

Reauthorization

- 1) Please provide the following information showing an attempt to decrease dose or trial and failure of an alternative therapy within the past year:
 - Date of dose reduction attempt: ______
 - Original dose member was prescribed:
 - Dose member was reduced to: ______
 - Outcomes of dose reduction: _____
 - Trial and failure of an alternative therapy (name of medication, date of trial, and an explanation as to how the member failed):
- 2) Please provide documentation showing continued benefit from the medication (i.e., reduction in frequency of cataplexy, reduction in symptoms of excessive daytime sleepiness, etc.) without significant adverse events (documentation must include most recent chart notes)

nitial Authoria	
Select	ONE of the following: The member is 7 years of age or older and has narcolepsy with cataplexy or excessive
1)	
	daytime sleepiness diagnosis □ Yes □ No
	 Please provide requested dose per day:
	• Please provide member's weight (include date of collection).
2)	The member is 18 years of age or older has idiopathic hypersomnia \Box Yes \Box No
	Please provide requested dose per day:
Reauthorizatio	
1)	 Please provide the following information showing an attempt to decrease dose or trial and failure of an alternative therapy within the past year: Date of dose reduction attempt:
	Original dose member was prescribed:
	Dose member was reduced to:
	Outcomes of dose reduction:
	• Trial and failure of an alternative therapy (name of medication, date of trial, and an
	explanation as to how the member failed):
2) Ple	ease provide documentation showing continued benefit from the medication (i.e., reduction in
fre	quency of cataplexy, reduction in symptoms of excessive daytime sleepiness, etc.) without
	nificant adverse events (documentation must include most recent chart notes)

CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.